vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Getty Images Holdings, Inc. (GETY). Click either name above to swap in a different company.
Getty Images Holdings, Inc. is the larger business by last-quarter revenue ($282.3M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -32.2%, a 43.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 14.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $7.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 12.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Getty Images Holdings, Inc. is a visual media company and supplier of stock images, editorial photography, video, and music for businesses and consumers, with a library of over 477 million assets. It targets three markets—creative professionals, the media, and corporate.
ANIP vs GETY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $282.3M |
| Net Profit | $27.5M | $-90.9M |
| Gross Margin | — | 74.8% |
| Operating Margin | 14.1% | -8.5% |
| Net Margin | 11.1% | -32.2% |
| Revenue YoY | 29.6% | 14.1% |
| Net Profit YoY | 367.5% | -467.6% |
| EPS (diluted) | $1.14 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $282.3M | ||
| Q3 25 | $227.8M | $240.0M | ||
| Q2 25 | $211.4M | $234.9M | ||
| Q1 25 | $197.1M | $224.1M | ||
| Q4 24 | $190.6M | $247.3M | ||
| Q3 24 | $148.3M | $240.5M | ||
| Q2 24 | $138.0M | $229.1M | ||
| Q1 24 | $137.4M | $222.3M |
| Q4 25 | $27.5M | $-90.9M | ||
| Q3 25 | $26.6M | $21.6M | ||
| Q2 25 | $8.5M | $-34.4M | ||
| Q1 25 | $15.7M | $-102.6M | ||
| Q4 24 | $-10.3M | $24.7M | ||
| Q3 24 | $-24.2M | $-2.5M | ||
| Q2 24 | $-2.3M | $3.7M | ||
| Q1 24 | $18.2M | $13.6M |
| Q4 25 | — | 74.8% | ||
| Q3 25 | — | 73.2% | ||
| Q2 25 | — | 72.1% | ||
| Q1 25 | — | 73.1% | ||
| Q4 24 | — | 73.5% | ||
| Q3 24 | — | 73.4% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 72.9% |
| Q4 25 | 14.1% | -8.5% | ||
| Q3 25 | 15.9% | 18.8% | ||
| Q2 25 | 6.6% | 15.1% | ||
| Q1 25 | 13.3% | 12.2% | ||
| Q4 24 | -2.3% | 14.5% | ||
| Q3 24 | -13.8% | 23.9% | ||
| Q2 24 | 3.7% | 20.3% | ||
| Q1 24 | 14.8% | 18.5% |
| Q4 25 | 11.1% | -32.2% | ||
| Q3 25 | 11.7% | 9.0% | ||
| Q2 25 | 4.0% | -14.6% | ||
| Q1 25 | 8.0% | -45.8% | ||
| Q4 24 | -5.4% | 10.0% | ||
| Q3 24 | -16.3% | -1.1% | ||
| Q2 24 | -1.7% | 1.6% | ||
| Q1 24 | 13.2% | 6.1% |
| Q4 25 | $1.14 | $-0.22 | ||
| Q3 25 | $1.13 | $0.05 | ||
| Q2 25 | $0.36 | $-0.08 | ||
| Q1 25 | $0.69 | $-0.25 | ||
| Q4 24 | $-0.45 | $0.07 | ||
| Q3 24 | $-1.27 | $-0.01 | ||
| Q2 24 | $-0.14 | $0.01 | ||
| Q1 24 | $0.82 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $90.2M |
| Total DebtLower is stronger | — | $1.3B |
| Stockholders' EquityBook value | $540.7M | $552.5M |
| Total Assets | $1.4B | $3.2B |
| Debt / EquityLower = less leverage | — | 2.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $90.2M | ||
| Q3 25 | $262.6M | $109.5M | ||
| Q2 25 | $217.8M | $110.3M | ||
| Q1 25 | $149.8M | $114.6M | ||
| Q4 24 | $144.9M | $121.2M | ||
| Q3 24 | $145.0M | $109.9M | ||
| Q2 24 | $240.1M | $121.7M | ||
| Q1 24 | $228.6M | $134.2M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $540.7M | $552.5M | ||
| Q3 25 | $505.8M | $634.6M | ||
| Q2 25 | $436.8M | $611.2M | ||
| Q1 25 | $418.6M | $593.0M | ||
| Q4 24 | $403.7M | $670.2M | ||
| Q3 24 | $405.9M | $683.4M | ||
| Q2 24 | $455.8M | $654.0M | ||
| Q1 24 | $452.0M | $640.8M |
| Q4 25 | $1.4B | $3.2B | ||
| Q3 25 | $1.4B | $2.6B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.3B | $2.6B | ||
| Q2 24 | $920.8M | $2.6B | ||
| Q1 24 | $914.5M | $2.6B |
| Q4 25 | — | 2.30× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | — | 2.21× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 2.06× | ||
| Q1 24 | — | 2.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $20.6M |
| Free Cash FlowOCF − Capex | $29.1M | $7.7M |
| FCF MarginFCF / Revenue | 11.8% | 2.7% |
| Capex IntensityCapex / Revenue | 0.5% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $20.6M | ||
| Q3 25 | $44.1M | $22.6M | ||
| Q2 25 | $75.8M | $6.5M | ||
| Q1 25 | $35.0M | $15.4M | ||
| Q4 24 | $15.9M | $39.7M | ||
| Q3 24 | $12.5M | $10.7M | ||
| Q2 24 | $17.4M | $46.4M | ||
| Q1 24 | $18.3M | $21.5M |
| Q4 25 | $29.1M | $7.7M | ||
| Q3 25 | $38.0M | $7.9M | ||
| Q2 25 | $71.8M | $-9.6M | ||
| Q1 25 | $32.5M | $-322.0K | ||
| Q4 24 | $13.5M | $24.6M | ||
| Q3 24 | $7.7M | $-1.8M | ||
| Q2 24 | $13.0M | $31.1M | ||
| Q1 24 | $13.7M | $7.1M |
| Q4 25 | 11.8% | 2.7% | ||
| Q3 25 | 16.7% | 3.3% | ||
| Q2 25 | 34.0% | -4.1% | ||
| Q1 25 | 16.5% | -0.1% | ||
| Q4 24 | 7.1% | 9.9% | ||
| Q3 24 | 5.2% | -0.8% | ||
| Q2 24 | 9.4% | 13.6% | ||
| Q1 24 | 10.0% | 3.2% |
| Q4 25 | 0.5% | 4.6% | ||
| Q3 25 | 2.7% | 6.1% | ||
| Q2 25 | 1.9% | 6.9% | ||
| Q1 25 | 1.3% | 7.0% | ||
| Q4 24 | 1.3% | 6.1% | ||
| Q3 24 | 3.2% | 5.2% | ||
| Q2 24 | 3.2% | 6.7% | ||
| Q1 24 | 3.3% | 6.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 1.05× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.59× | ||
| Q1 24 | 1.00× | 1.58× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GETY
| Creative | $149.0M | 53% |
| Editorial | $109.4M | 39% |
| Other | $23.9M | 8% |
